Lu, B., Nakamura, T., Inouye, K., Li, J., Tang, Y., Lundback, P., Valdes-Ferrer, S.I., Olofosson, P., Kalb, T., Roth, J., Zou, Y., Erlandsson-Harris, H., Yang, H., Ting, J.P., Wang, H., Andersson, U., Antoine, D.J., Chavan, S.S., Hotamisiligil, G.S. and Tracey, K.J. (2012) Novel Role of PKR in Inflammasome Activation and HMGB1 Release. Nature, 488, 670-674.
https://doi.org/10.1038/nature11290

has been cited by the following article:

• TITLE: The Analysis of the Effective Systemic Lidocaine Dosage on the Expression of HMGB1 mRNA on Mice with Sterile Musculoskeletal Injury

  AUTHORS: Robert Hotman Sirait, Mochammad Hatta, Muhammad Ramli, Tigor Peniel Simanjuntak, Bambang Suprayogi, Andi Asadul Islam, Syafrie Kamsul Arief

  KEYWORDS: High Mobility Group Box 1, Lidocaine, Musculoskeletal Injury

  JOURNAL NAME: Open Journal of Anesthesiology, Vol.7 No.2, February 27, 2017

  ABSTRACT: A severe injury can trigger an inflammation response and excessive response can cause multiple organ failure. HMGB1 is an early inflammation mediator in sterile injury and a late inflammation mediator in infection. It is an important mediator in severe sepsis and always associated with the severity of organ failure. Previous studies showed that the administration of systemic lidocaine could inhibit the expression of HMGB1 on septic mice with musculoskeletal injury. Nine male adult Balb/c mice were grouped by simple random sampling method into three groups of intravenous lidocaine injection dosages: 2 mg/kg, 3 mg/kg, 4 mg/kg. Musculoskeletal injury was done by breaking the left femoral bone in a close manner. Peripheral blood sampling was done 4 hours after injury and 2 hours after lidocaine therap. To evaluate the expression level of HMGB1 mRNA, RT-PCR was used. The result of our study showed that intravenous lidoaine administration on the 3 groups could decrease the level of HMGB1. In conclusion, lidocaine hold an important role in clinical diseases by inhibiting HMGB1.